Markets
Skye Bioscience, Inc. (SKYE)
SKYEStock
$1.09
+0.0100 (+0.93%) today
Closed, Nov 13, 4:00 PM ET
+0.93% 1D
- Market cap
- –
- P/E
- –
- EPS, last 4 quarters
- $-10.16
- Dividend yield
- –
- Day range
- –
- 52-week range
- –
- Average volume
- –
- Previous close
- $1.08
Earnings
Next report Nov 16, 2026
Sep 2025
+3.0%
Dec 2025
-24.1%
Mar 2026
-10.3%
Jun 2026
+6.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$13.27m | -$14.90m | -$12.67m | -$11.06m |
| Net income | -$12.76m | -$14.44m | -$12.51m | -$10.79m |
News
8 latest- Skye Bioscience, Inc. Wins Unanimous Jury Verdict in Whistleblower Retrial on November 10, 2026Fintel · 2 days ago
- Skye Bioscience Average Analyst Price Target Raised 10.29% to $61.20Fintel · Sep 15, 2026
- Weekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks RTTNews · Aug 21, 2026
- Skye To Acquire Redx; $125M Financing Secures Path To RXC008 Phase 2 Trial; Stock Up RTTNews · Aug 17, 2026
- Skye Bioscience, Redx Pharma To Combine To Operate As Fibrx Therapeutics RTTNews · Aug 14, 2026
- Skye Receives CRC Approval For Cohort 2 In Nimacimab Expansion Study For Obesity RTTNews · May 21, 2026
- Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected RTTNews · Feb 6, 2026
- Skye Reports Positive Data From Extension Phase Of Phase 2a CBeyond Trial In Obesity RTTNews · Feb 2, 2026
The company
Skye Bioscience, Inc. (Nasdaq: SKYE) is a clinical-stage biotechnology company. Its lead program has been nimacimab, a negative allosteric modulating antibody that peripherally inhibits the CB1 receptor, developed for weight loss in patients with obesity or overweight and evaluated in the CBeyond Phase 2a trial. Additional information is contained in Skye's periodic reports filed with the SEC. For more information, visit www.skyebioscience.com.
- Region
- North America
- Website
- skyebioscience.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.